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Background: Some evidence suggests that antidepressants may relate to poor
outcomes in depression. The aim of this study was, therefore, to examine, whether
antidepressant use may worsen the long-term outcome in real-world psychiatric patients
with both primarily affective and non-affective mental disorders.
Methods: Based on a total of n = 151 inpatients with a mixed range of diagnoses
enrolled at two psychiatric hospitals in Zurich, Switzerland, matched pairs of n = 45
antidepressant users and n = 45 non-users were selected via nearest neighbor
propensity score matching. Pairs were matched according to 14 clinically relevant
covariates assessing psychosocial impairments, functioning deficits and illness severity.
The two outcomes of interest were the number and total duration of all rehospitalisations
over a 12-month follow-up after discharge from the hospital based on the official
clinical registry.
Results: Altogether 35.6% of antidepressant users were rehospitalised at least once,
as compared to 22.2% in matched non-users. Two or more rehospitalisations occurred
in 22.2% of antidepressant users but only in 2.2% of non-users. In antidepressant users,
the mean total duration of rehospitalisations was 22.22 days, as compared to 8.51
in matched non-users. According to Poisson regression analyses, antidepressant use
during acute inpatient care prospectively relates to both a higher risk (incidence rate ratio
[IRR] = 3.64, 95% confidence interval [95%-CI] = 1.71–7.75, p = 0.001) and a longer
duration (IRR= 2.61, 95%-CI= 1.01–6.79, p= 0.049) of subsequent rehospitalisations.
These findings were consistently replicated when traditional multivariable regression
analysis was applied to the full sample. Findings also replicated when patients with
affective and non-affective disorders were analyzed separately.
Hengartner et al. Antidepressants and Risk of Rehospitalisation
Conclusions: Our findings raise the possibility that, in the long-term, antidepressants
may impair recovery and increase the risk of rehospitalisation in patients with both
primarily affective and non-affective disorders. More work is required to explore possible
aetiopathological pathways leading to psychiatric rehospitalisation.
Keywords: antidepressants, affective disorders, depression, outcome, rehospitalisation, propensity score
INTRODUCTION
The persistent increase in antidepressant drug prescriptions
over the last three decades left the global prevalence of
major depression and anxiety disorders largely unchanged
(1), whereas disability owing to affective disorders has even
increased on a population level (2, 3). This is a paradox if
we assume that antidepressants effectively facilitate remission
and prevent relapse in the long-term. As a result, the long-
term benefits of antidepressant pharmacotherapy have
been contested (4–6). In the following we will provide
are brief overview of the pertinent literature on this
controversial issue.
Evidence From Discontinuation Trials
The evidence for long-term benefits of antidepressants relies
mainly on discontinuation trials, in which remitted/recovered
patients on antidepressants are randomized to either abrupt
switching to placebo (i.e., treatment discontinuation) or
continuing drug use (i.e., maintenance therapy). These
discontinuation trials indeed suggest that antidepressants
may prevent depression relapse [for a recent meta-analysis,
see for instance (7)], but the validity of these studies is
limited. First, they include only patients who responded to
acute drug treatment, hence, the results do not apply to the
many patients who recover spontaneously or to patients
who do not respond to the drugs. Second, the control group
consists of drug-responders who were randomized to have
the drug discontinued rapidly and replaced by placebo, hence
placebo-controls may experience withdrawal syndromes
which may be misdiagnosed as depression relapse or which
themselves may cause relapse due to their distressing nature
(5, 6, 8). Several authors have therefore suggested that higher
relapse rates after antidepressant discontinuation, relative to
continuing pharmacotherapy, are due to oppositional tolerance,
which describes an iatrogenic process of neurobiological
adaptation to prolonged pharmacological perturbation
(9–11). Consistent with the hypothesis that relapse rates
in discontinuation trials are mostly due to withdrawal
reactions, it has been shown that the relative risk of
relapse is highest during the first 1–3 months after drug
discontinuation; afterwards there is no risk difference between
those patients who stayed on the drugs and those who were
switched to placebo (8, 12, 13). Therefore, and although
recommendation for maintenance pharmacotherapy is largely
based on discontinuation trials, they cannot inform whether
antidepressant users, as compared to non-users, have a better
long-term outcome.
Evidence From Other Long-Term Trials and
From Observational Studies
In the following we will therefore briefly summarize the evidence
from other research designs, including placebo-controlled
parallel-arm long-term trials and prospective observational
studies. In two large pragmatic real-world trials based on
representative samples of patients with major depression, only
about 5% of continuously drug-treated participants achieved
sustained remission over 12 months (14, 15). That is, enduring
symptom remission is rare whereas relapse is very common
even in intensively drug-treated patients. Unfortunately, in
these two trials referenced above there was no un-medicated
control group, but mounting evidence suggests that untreated
patients may not have a worse outcome. For instance, a
meta-analysis of placebo-controlled long-term parallel-arm trials
of 6–8 months duration for major depression revealed that
antidepressant use may not improve remission rates (16).
In another meta-analysis it was further shown that patients
whose depression remitted while on placebo have a lower
relapse risk upon treatment discontinuation than patients
who were on antidepressants (9). What about evidence for
conditions other than major depression? In a recent 20-
week randomized trial of people with complicated grief, the
outcome for antidepressants did not differ from placebo, but
was significantly worse than the outcome for psychotherapy
in terms of functional impairment, depression symptoms, and
suicidality (17). Likewise, some long-term follow-ups of clinical
trials for anxiety disorders suggest that, relative to placebo (18)
or psychotherapy (19), antidepressants may impair recovery and
worsen the long-term outcome.
Of course this brief overview was not exhaustive, but it
demonstrates that there is compelling evidence from many
randomized controlled trials that antidepressants may not
improve long-term outcomes (5, 6). Unfortunately, all these
clinical trials (and their naturalistic follow-ups) either relied
on pre-selected, unrepresentative samples [e.g., (16, 19)] or
did not include an un-medicated control-group [e.g., (14, 15)].
Therefore, naturalistic observational studies based on real-world
patient samples drawn from routine care services and from
the general population are required. Such studies commonly
suggest that in people with affective disorders, antidepressant
use, compared to non-use, relates to a poorer long-term outcome
(20–26). These findings are frequently met with disbelief by
many experts in psychiatry. A common objection to findings
from observational studies therefore is that they are unreliable
due to selection bias. However, this assumption is empirically
unfounded. Meta-analytic research that systematically compared
treatment outcomes from observational studies with those from
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randomized trials does not indicate that treatment outcomes
differ by research design (27, 28).
The Present Study
Nevertheless, naturalistic observational studies certainly have
limitations. So far, most studies focused exclusively on patients
with major depression, and there is a lack of research on
the long-term outcome of antidepressant use in patients with
primarily non-affective mental disorders. Moreover, in previous
research on the outcome of antidepressant pharmacotherapy
the main outcome was typically based on assessments with
subjective depression rating-scales, which may have limited
validity (29, 30). Symptom rating scales may also fail to
adequately capture clinically significant functional outcomes
such as rehospitalisation and long-term disability. Confounding
by indication is another problem that threatens the validity
of observational studies (31). Although recent work has tried
to address this problem by including potential confounders as
covariates in multivariable regression models, such an approach
may not be sufficient. Selection bias is more adequately accounted
for with propensity score methods (32). In the present study
we will therefore focus on rehospitalisation rates derived from
a clinical registry, which is an objective and unbiased outcome.
Moreover, we will include patients with both primarily affective
and non-affective mental disorders and use propensity score
matching analysis to minimize selection bias.
The aim of the present work was thus to explore,
whether antidepressant use during an acute psychiatric inpatient
hospitalization predicts rehospitalisation rates over a 12-month
follow-up after discharge. Based on our previous analysis
of a prospective community sample (26), we hypothesized
that antidepressant use would prospectively relate to higher
rehospitalisation rates.
METHODS
Design and Procedure
We used data from the Post-Discharge Network Coordination
Programme (PDNC-P). The methods of this randomized
controlled trial have been described in detail elsewhere (33, 34).
In short, the trial was designed to test the outcome of a brief
case management intervention carried out by social workers.
The aim of this trial was to reduce rehospitalisation rates and to
increase long-term mental health and functioning in psychiatric
inpatients without a history of repeated hospitalisations. The
inclusion criteria were: (1) no more than three hospitalisations
within the last 3 years (including the index hospitalization),
(2) a Global Assessment of Functioning (GAF) score of 60 or
lower, (3) cognitive ability to provide written informed consent,
and (4) age between 18 and 64 years. Exclusion criteria were:
(1) insufficient German language proficiency, (2) simultaneous
support by another case manager, and (3) living in supportive
housing. The PDNC-P comprised two treatment arms: Half of the
participants were randomly assigned to a brief case management
intervention detailed in Hengartner et al. (35) and the other half
received treatment as usual (i.e., no coordinated support after
discharge). Both groups were assessed during acute inpatient care
(t0), 3 months after discharge when the intervention terminated
(t1), and 12months after discharge (t2). Participants and assessors
were blind toward group allocation at baseline measurement t0.
The recruitment began in September 2011 and the last follow-up
assessment of t2 was carried out in April 2015. Rehospitalisations
at 12-month follow-up (t2) were assessed for the full sample based
on the clinical registry.
The trial was approved by the cantonal ethics committee
of Zurich (reference number: KEK-ZH 2011-0175) and
pre-registered in the International Standard Randomized
Controlled Trial Number (ISRCTN) register (reference number:
ISRCTN58280620). The study protocol was published freely
available online (34).
Participants
The PDNC-P included 151 inpatients from the Winterhur—
Zurich Unterland psychiatric catchment area, an
urban/suburban area of high-level resources near the city
of Zurich, Switzerland. For more information, see references
(33, 34). The participants were enrolled at two different
psychiatric hospitals: the Psychiatrie-Zentrum Hard in Embrach
and the Klinik Schlosstal in Winterthur, which are both part of
the umbrella organization Integrierte Psychiatrie Winterthur—
Zürcher Unterland (IPW). The sample comprised 79 men
(51.7%) and 72 women (48.3%). Their mean age was 41.6 years
(SD = 11.3) and ranged from 18 to 61 years. For n = 85 (56.3%)
it was the first hospitalization, for n= 45 (29.8%) the second and
for n = 21 (13.9%) the third hospitalization. A total of n = 37
(24.5%) had a primary diagnosis of substance-use disorder (SUD;
ICD-10 code F10-F19), n = 41 (27.2%) of schizophrenia and
other psychotic disorders (F20-F29), n = 52 (34.4%) of a mood
disorder (F30-F39, whereof n = 34 had a depressive disorder,
F32 or F33), and n = 21 (13.9%) had other disorders (whereof
n = 17 had an anxiety and stress-related disorder F41-F43;
n = 3 a personality disorder F60; and n = 1 an attention deficit
hyperactivity disorder F90). The three patients with personality
disorders and the one patient with attention deficit hyperactivity
disorder all had comorbid affective disorders (F32 and/or F43).
As a result, n= 78 patients (51.7%) were broadly classified with a
primarily non-affective disorder (comprising SUD and psychotic
disorders) and n = 73 (48.3%) with an affective disorder
(comprising mood, anxiety and stress-related disorders). A
total of n = 39 (25.8%) were prescribed a SSRI, n = 11 (7.3%)
with a TCA, and n = 11 (7.3%) other antidepressants. During
the index hospitalization altogether n = 54 (35.8%) used
an antidepressant, n = 48 (31.8%) used neuroleptics, and
n = 16 (10.6%) concurrently used both antidepressants and
neuroleptics. All antidepressant users were discharged from the
hospital with a continued antidepressant prescription.
Outcomes and Measures
Primary outcomes in the PDNC-P as well as in the present
study were the frequency and the duration of rehospitalisations
over the 12-month observation period following discharge
as assessed with the IPW clinical registry (t2 assessment).
Frequency of rehospitalisations was defined as the total number
of readmissions, whereas duration of rehospitalisations was
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TABLE 1 | Clinical and socio-demographic characteristics of antidepressant (AD)
users and non-users.
No AD use
(n = 45)
AD use
(n = 45)
P
Sex Men 22 (48.9) 23 (51.1) 1.000 a
Women 23 (51.1) 22 (48.9)
Age Years 43.2 (11.4) 43.0 (10.4) 0.931 b
Relationship status Single 22 (51.2) 21 (48.8) 1.000 a
In relationship 23 (48.9) 24 (51.1)
Education level High 10(47.6) 11 (52.4) 1.000 a
Other 35 (50.7) 34 (49.3)
Receipt of state benefits Yes 25 (49.0) 26 (51.0) 1.000 a
No 20 (51.3) 19 (48.7)
Index admission First 24 (51.1) 23 (48.9) 1.000 a
Second or third 21 (48.8) 22 (51.2)
Primary disorder Affective 24 (49.0) 25 (51.0) 1.000 a
Non-affective 21 (51.2) 20 (48.8)
Neuroleptic use Yes 14 (50.0) 14 (50.0) 1.000 a
No 31 (50.0) 31 (50.0)
Psychopathology
(assessor-rated)
HoNOS 1.4 (0.5) 1.4 (0.4) 0.742 b
Psychopathology
(self-rated)
OQ45 78.3 (29.7) 77.7 (18.5) 0.909 b
Perceived social support FsozU 3.6 (0.9) 3.6 (0.9) 0.843
Social functioning SOFAS 42.8 (13.1) 41.4 (11.1) 0.592
Global functioning GAF 36.0 (12.5) 34.8 (10.3) 0.639
Subjective quality of life MANSA 4.3 (1.2) 4.2 (0.9) 0.697
Categorical variables are reported with number and percent (in brackets) and continuous
variables with mean and standard deviation (in brackets).
aFisher’s Exact Test (two-sided); b Independent-samples T-Test (two-sided).
defined as the sum of all inpatient days over all readmissions.
For instance, when a patient was rehospitalised twice, the first
time for 10 days and the second time for 20 days, then his/her
number of rehospitalisations was 2 and the total duration of
rehospitalisations was 30 days. Another patient may also have
2 rehospitalisations, the first for 20 days and the second for 30
days, which adds up to a total of 50 days. That is, although
both exemplary patients had 2 rehospitalisations, they differed
in their total length of rehospitalisations. Since all psychiatric
hospitalisations within the IPW catchment area are recoded in
the clinical registry, there were no missing data.
Antidepressant use and socio-demographics were assessed
with the Client Socio-Demographic and Service Receipt
Inventory—European Version [CSSRI-EU; (36)] during acute
inpatient care (t0 assessment). We further included the following
variables assessed during acute inpatient care (t0 assessment): A
patients’ functioning at baseline was rated by a blinded assessor
with the Social and Occupational Assessment Scale [SOFAS;
(37)] as well as with the GAF score (38). Social support was
measured with the “Fragebogen zur sozialen Unterstützung—
Kurzform 14” [F-SozU; (39)]. The F-SozU is a German
self-rating questionnaire comprising items from the following
three domains of perceived social support: emotional support,
instrumental support, and social integration. Psychopathology
and illness severity were assessed via assessor-rating using the
Health of the Nation Outcome Scales [HoNOS; (40)] as well as
via patients’ self-rating using the Outcome Questionnaire 45
[OQ-45, German version; (41)]. Finally, subjective quality of life
was rated by the patients with the Manchester Short Assessment
of Quality of Life [MANSA; (42)].
Statistical Analysis
We extracted matched pairs of antidepressant users and non-
users based on propensity score analysis (43). As recommended
in the literature (32), we used nearest neighbor matching
based on logistic regression and a maximal caliper distance
of 0.2. Propensity score matching assigns a control subject
to an experimental subject via the multivariate analysis of
covariates. By this means antidepressant users are compared
to non-users that are similar with respect to various clinically
relevant variables that were selected a priori. We included the
following 14 covariates: sex (men vs. women), age (in years),
relationship status (single vs. in relationship) education level
(high vs. other), receipt of state benefits (yes vs. no), first
hospitalization at index (yes vs. no), primary disorder (affective
vs. non-affective), neuroleptic use (yes vs. no), assessor-rated
severity of psychopathology (HoNOS), subjective severity of
psychopathology (OQ45), perceived social support (FsozU),
social functioning (SOFAS), global level of functioning (GAF),
and subjective quality of life (MANSA). The case management
intervention to which half of all participants were assigned in this
trial had no effect on rehospitalisation rates and therefore was
omitted from the analysis [for a detailed account, see reference
(33)]. The prospective associations between antidepressant use
during acute inpatient care (t0 assessment) and the frequency and
duration of rehospitalisations within 12 months after discharge
(t2 assessment) were examined with a series of Poisson regression
analyses with log link-function. Poisson regression was chosen
because both outcomes were right-skewed counts (i.e., non-
negative integer values). Antidepressant use was entered as
the predictor variable and both frequency and duration of
rehospitalisations separately as the outcome variable. Findings of
the Poisson regression analyses were reported with the incidence
rate ratio (IRR), which is a convenient effect size to evaluate
to effect of different predictor variables on Poisson-distributed
outcomes. All analyses were conducted with SPSS version 24
for Windows.
RESULTS
Out of a base of n = 151 inpatients, comprising n = 54
(35.8%) antidepressant users and n = 97 (64.2%) non-users,
propensity score matching analysis extracted 45 matched pairs
(i.e., 45 antidepressant users and 45 non-users). The paired
dataset included n = 45 men and women each with a mean age
(SD) of 43.1 (10.8) years. A total of n = 49 (54.4%) inpatients
had primarily an affective disorder (depression, anxiety, and
stress-related disorders), and n = 41 (45.6%) a non-affective
disorder (SUD and psychotic disorders). For n = 47 (52.2%) it
was the first hospitalization in the last 3 years. Table 1 shows the
distribution of the 14 covariates on which basis antidepressant
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TABLE 2 | Number and frequency (in brackets) of primary diagnoses in
antidepressant (AD) users and non-users in the propensity score matched sample
(n = 90).
No AD use
(n = 45)
AD use
(n = 45)
P
Alcohol use disorder (F10) 4 (8.9) 12 (26.7) 0.027
Polysubstance abuse (F19) 1 (2.2) 1 (2.2) 1.0
Schizophrenia (F20) 11 (24.4) 3 (6.7) 0.020
Acute psychotic disorder (F23) 2 (4.4) 1 (2.2) 0.557
Schizoaffective disorder (F25) 2 (4.4) 2 (4.4) 1.0
Bipolar disorder (F31) 8 (17.8) 4 (8.9) 0.215
Depression episode (F32) 4 (8.9) 8 (17.8) 0.215
Recurrent depression (F33) 5 (11.1) 4 (8.9) 0.725
Panic disorder (F41) 1 (2.2) 2 (4.4) 0.557
Severe stress and adjustment disorder (F43) 4 (8.9) 4 (8.9) 1.0
users were matched to corresponding non-users. There were no
differences between pairs of users and non-users and the two
groups were perfectly balanced (overall balance test: χ2 = 1.626,
df = 14, p = 1.000; number of unbalanced covariates: 0). A
detailed description of specific primary diagnoses is provided in
Table 2. A primary diagnosis of alcohol use disorder was more
common among antidepressant users, whereas schizophrenia
was more frequent among non-users, but both comparisons did
not reach statistical significance after correcting for multiple
testing (α = 0.005).
In antidepressant users (n = 45), the number of
rehospitalisations ranged from 0 to 6. A total of 16 patients
(35.6%) had at least 1 rehospitalisation, 10 (22.2%) had 2
or more rehospitalisations and 7 patients (15.6%) had 3 or
more rehospitalisations. In the matched non-users (n = 45),
the number of rehospitalisations ranged from 0 to 2 and
10 patients (22.2%) had at least 1 rehospitalisation. Only 1
patient (2.2%) had 2 rehospitalisations. A detailed account is
provided in Table 3. The total duration of rehospitalisations
ranged from 0 to 191 days, with a mean (SD) 22.22 (40.61)
in antidepressant users, and from 0 to 112, with a mean (SD)
of 8.51 (23.46) in non-users. The corresponding boxplots are
shown in Figure 1. The results of the Poisson regression analysis
showed that antidepressant use was prospectively associated
with a significantly increased number (IRR=3.64, 95%-CI=1.71-
7.75, p = 0.001) and duration (IRR=2.61, 95%-CI=1.01-6.79,
p= 0.049) of subsequent rehospitalisations.
As part of a sensitivity analysis we aimed at reproducing our
results with traditional multivariable regression analysis in the
full sample. For it we conducted two Poisson regression analyses,
first with number of rehospitalisations as the outcome and second
with duration of rehospitalisations as the outcome. In both
models we included antidepressant use as the main predictor
variable and the following potential confounders as control
variables: sex, age, education level, relationship status, receipt
of state benefits, primary diagnosis, neuroleptic use, number
of index admission, other-rated severity of psychopathology
(HoNOS), global level of functioning (GAF), subjective quality
of life (MANSA), social functioning (SOFAS), self-rated severity
TABLE 3 | Number of psychiatric rehospitalisations within 12-months after
discharge from the index hospitalization in n = 45 antidepressant users and
n = 45 propensity-score matched non-users.
Number of
rehospitalisations
Frequency Percent Cumulative
Percent
AD users 0 29 64.4 64.4
1 6 13.3 77.8
2 3 6.7 84.4
3 3 6.7 91.1
4 2 4.4 95.6
5 1 2.2 97.8
6 1 2.2 100
Non-users 0 35 77.8 77.8
1 9 20.0 97.8
2 1 2.2 100
of psychopathology (OQ45 sum score), and perceived social
support (FsozU). Due to some missing values in the covariates,
n = 131 patients, whereof n = 49 antidepressant users, were
included in this analysis. Consistent with our propensity score
matching analysis, antidepressant use related to both a higher
number of rehospitalisations (IRR = 3.71, 95%-CI = 1.87-7.36,
p < 0.001) and to a longer duration of rehospitalisations (IRR
= 6.14, 95%-CI = 2.25-16.74, p < 0.001). When patients with
bipolar disorder were excluded, n = 44 antidepressant users
and n = 73 non-users remained in the dataset. A re-analysis
with this restricted sample (n = 117) yielded similar results
(for number of rehospitalisations: IRR=4.28, 95%-CI=2.10-8.70,
p < 0.001; for duration of rehospitalisations: IRR=6.16, 95%-
CI=2.42-15.72, p< 0.001).
We also re-conducted our analysis stratified according to
primary diagnostic group. In patients with non-affective primary
diagnosis (n = 67, whereof n = 21 antidepressant users),
controlling for all other covariates, antidepressant use related
to both higher number (IRR = 3.70, 95%-CI = 1.87–7.34,
p< 0.001) and longer duration of rehospitalisations (IRR= 6.10,
95%-CI = 1.67–22.22, p = 0.006). Likewise, in patients with
an affective primary diagnosis (n = 64, whereof n = 28
antidepressant users), antidepressants related to both higher
number (IRR= 3.47, 95%-CI= 1.34–9.00, p= 0.010) and longer
duration of rehospitalisations (IRR = 8.25, 95%-CI = 2.78–
24.47, I, p< 0.001).
DISCUSSION
Summary
In this prospective naturalistic observational study we
related antidepressant use during acute hospital care to
subsequent rehospitalisations over a 12-month follow-up after
discharge in a propensity score matched sample of n = 90
psychiatric inpatients with primarily affective (mood, anxiety,
and stress-related disorders) and non-affective disorders
(substance-use and psychotic disorders). The results indicate
that antidepressant use during acute inpatient care relates to
3.5-fold increased risk of experiencing a rehospitalisation and
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FIGURE 1 | Boxplots for total duration of rehospitalizations (in days) for antidepressant users and non-users. Asterisk indicate single outliers.
to a 2.5-fold increased duration of total days rehospitalised
over 12 months. The results were replicated when instead of
propensity score matching analysis a less stringent, traditional
multivariable regression analysis was applied to the full sample
of n = 131 participants. Moreover, all effects were replicated
when patients with bipolar disorder were excluded from the
analysis and when affective and non-affective disorders were
analyzed separately.
Strengths and Limitations
The strengths of the present work comprise its prospective
design, thorough assessment of various clinically important
covariates and an unbiased, objective study outcome. The
main improvement over previous observational studies is
the sophisticated statistical adjustment for selection bias (i.e.,
confounding by indication). Based on a nearest neighbor
propensity score matching analysis we selected a group of
antidepressant users that was perfectly matched to non-users
based on 14 clinically important covariates. By this means
we were able to minimize confounding by indication in non-
random treatment groups (32). Although many researchers
and clinicians falsely believe that the results of observational
studies are not reliable, it is important to emphasize that
healthcare outcomes assessed with observational studies do not
differ systematically from those assessed in randomized clinical
trials (27, 28).
Nevertheless, our study has important limitations, which
we critically acknowledge before we proceed with a thorough
discussion of our findings. First, and most importantly, patients
were not randomly assigned to antidepressant use, which
precludes causal conclusions. Although we matched drug-
users with similar non-users based on 14 covariates, including
psychosocial impairments, illness severity and functioning
deficits, we cannot rule out that there are unmeasured
confounders which introduced selection bias. Second, with
n = 90 the propensity score matched sample was rather
modest. Future studies with larger samples are necessary to
increase power and precision. Third, we did not assess for
how long the patients continued antidepressant use after
discharge from the hospital. Fourth, we do not know for which
reasons participants were rehospitalised. The specific cause of
rehospitalisation could help to work out possible etiological
mechanisms linking antidepressant use to the re-occurrence of
acutely distressing psychopathology.
Interpretation of Findings
Several long-term trials suggest that antidepressants may not
produce clinically meaningful long-term benefits (14–16). In
accordance with mounting evidence from observational studies,
our findings even raise the possibility that antidepressant
pharmacotherapy may increase relapse rates and impair recovery
in the long run (20, 21, 23, 24, 26). These findings are in
accord with a comprehensive meta-analysis of long-term clinical
trials by Andrews et al. (9), which shows that patients with
major depression who recovered on placebo have a lower
relapse rate upon treatment discontinuation than patients who
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recovered on drugs. These findings conflict with the results
from discontinuation trials (7), which aim at estimating long-
term relapse prevention in continuously drug-treated patients
compared to patients whosemedication was discontinued rapidly
and replaced by placebo.
Although recommendation for maintenance therapy is mostly
based on these discontinuation trials, their validity is poor due
to several limitations (5, 6). Since antidepressant discontinuation
can cause severe withdrawal reactions, including depression-
like symptoms such as lethargy, fatigue, irritability, suicidal
ideation, and sleep problems (44), withdrawal reactions are easily
misdiagnosed as depression relapse (8, 13, 44). The higher relapse
rates in participants switched to placebo could thus be the result
of neurobiological adaptations due to prior pharmacotherapy, a
condition that was referred to as oppositional tolerance (4, 9).
Moreover, preventive effects reported in discontinuation trials
apply only to patients who favorably respond to antidepressant,
but not to non-responders and spontaneous remitters (16).
As there appears to be an association between antidepressant
use and rehospitalisation rates, it is important to propose
plausible causal mechanisms that may account for such
a relationship. Although we were not able to assess these
mechanisms in our study, possible pathways have been described
in the literature. Owing to pharmacodynamic alterations in
neurobiological functions, including reduction of receptor
density in response to increased neurotransmitter concentration
(45), affective and psychosomatic disturbances following
long-term antidepressant use are possibly iatrogenic, that
is, attributable to drug-induced neurobiological adaptations
(4, 9, 10). These treatment-emergent adverse effects of
psychotropic medications may develop following antidepressants
discontinuation of mostly long-term use and in some patients
withdrawal is severe to an extent that they develop protracted
post-withdrawal affective disorders (44, 46). In other instances
continuing antidepressant therapy after initial response may
cause new mental disorders, which has also been referred to as
behavioral toxicity (46).
Meta-analyses of placebo-controlled randomized trials indeed
suggest that some rehospitalisations in treatment-adherent
antidepressant users are possibly due to adverse drug reactions.
For instance, in patients with mood and anxiety disorders,
antidepressants may trigger psychomotor agitation and mania
(47, 48) or suicidal acts (49, 50). Moreover, in healthy volunteers
without mental disorders, relative to placebo, antidepressant
use has been associated with a significantly increased risk
of adverse mental events, including agitation, sleep problems,
nervousness, and abnormal thinking (51, 52). These iatrogenic
psychological disturbances may possibly account for the
increased rate and duration of rehospitalisations observed in
the present study, but more work is required to establish causal
aetiopathological mechanisms.
CONCLUSIONS
Our data suggest that antidepressant use during acute inpatient
care, compared to non-use, may increase the risk and duration
of subsequent rehospitalisations over a 12-month follow-up in
patients with both primarily affective and non-affective disorders.
Our findings therefore challenge the alleged long-term benefit of
antidepressants and raise the possibility, that, in the long run,
antidepressants may possibly do more harm than good (4, 5, 53,
54). The naturalistic design of our study does not allow for causal
conclusions, yet we suggest that it provides a signal that warrants
more research. In particular, we suggest that more attention
should be paid to possible iatrogenic effects of long-term
antidepressant pharmacotherapy, which still is an insufficiently
researched topic. Future work should explore potential causal
pathways, such as for instance agitation, emotional numbing
and/or neurobiological susceptibility to acute stress, through
which antidepressant use may impair long-term functioning
and well-being. Severe and sometimes protracted withdrawal
reactions after drug taper are another important but under-
researched topic. That is, higher rehospitalisation rates in
antidepressant users could be due to adverse reactions to long-
term antidepressant use (10) or the result of severe withdrawal
reactions upon drug discontinuation (44). These potential
mechanisms are tentative and still inconclusive, but they provide
an important avenue for future research into the long-term effects
of antidepressants.
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